These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31725651)

  • 41. Association between Thyroid Function and Nonalcoholic Fatty Liver Disease in Euthyroid Type 2 Diabetes Patients.
    Huang B; Yang S; Ye S
    J Diabetes Res; 2020; 2020():6538208. PubMed ID: 32964054
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Study of reactive oxygen species and adiponectin for chronic HBV infection combined with nonalcoholic fatty liver diseases].
    Xu L; Zhong Y; Su ST; Liu YG; Lyu FN; Zhou XL; Ren JQ; Li P; Shi RF; Jiang Y; Fan JG; Mi YQ
    Zhonghua Gan Zang Bing Za Zhi; 2020 Mar; 28(3):247-253. PubMed ID: 32306658
    [No Abstract]   [Full Text] [Related]  

  • 43. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
    Kim SK; Kim KI; Kim SR
    Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Effects of Hepatic Steatosis on the Natural History of HBV Infection.
    Suliman I; Abdelgelil N; Kassamali F; Hassanein TI
    Clin Liver Dis; 2019 Aug; 23(3):433-450. PubMed ID: 31266618
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
    Paschos P; Athyros VG; Tsimperidis A; Katsoula A; Grammatikos N; Giouleme O
    Curr Vasc Pharmacol; 2018; 16(3):269-275. PubMed ID: 28676018
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis.
    Yang RX; Pan Q; Liu XL; Zhou D; Xin FZ; Zhao ZH; Zhang RN; Zeng J; Qiao L; Hu CX; Xu GW; Fan JG
    Lipids Health Dis; 2019 Oct; 18(1):179. PubMed ID: 31639005
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PPARGC1A rs8192678 G>A polymorphism affects the severity of hepatic histological features and nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.
    Zhang RN; Shen F; Pan Q; Cao HX; Chen GY; Fan JG
    World J Gastroenterol; 2021 Jul; 27(25):3863-3876. PubMed ID: 34321850
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Subclinical hypothyroidism as a risk factor for the development of cardiovascular disease in obese adolescents with nonalcoholic fatty liver disease.
    Sert A; Pirgon O; Aypar E; Yilmaz H; Odabas D
    Pediatr Cardiol; 2013 Jun; 34(5):1166-74. PubMed ID: 23344895
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
    Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
    Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
    Harrison SA; Gawrieh S; Roberts K; Lisanti CJ; Schwope RB; Cebe KM; Paradis V; Bedossa P; Aldridge Whitehead JM; Labourdette A; Miette V; Neubauer S; Fournier C; Paredes AH; Alkhouri N
    J Hepatol; 2021 Aug; 75(2):284-291. PubMed ID: 33746083
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease.
    Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y
    Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.
    Haga Y; Kanda T; Sasaki R; Nakamura M; Nakamoto S; Yokosuka O
    World J Gastroenterol; 2015 Dec; 21(46):12989-95. PubMed ID: 26675364
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thyroid Function and the Risk of Nonalcoholic Fatty Liver Disease: The Rotterdam Study.
    Bano A; Chaker L; Plompen EP; Hofman A; Dehghan A; Franco OH; Janssen HL; Darwish Murad S; Peeters RP
    J Clin Endocrinol Metab; 2016 Aug; 101(8):3204-11. PubMed ID: 27270473
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity.
    Tsochatzis E; Papatheodoridis GV; Hadziyannis E; Georgiou A; Kafiri G; Tiniakos DG; Manesis EK; Archimandritis AJ
    Scand J Gastroenterol; 2008; 43(9):1128-36. PubMed ID: 18609175
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease.
    Goh GB; Issa D; Lopez R; Dasarathy S; Dasarathy J; Sargent R; Hawkins C; Pai RK; Yerian L; Khiyami A; Pagadala MR; Sourianarayanane A; Alkhouri N; McCullough AJ
    J Gastroenterol Hepatol; 2016 May; 31(5):995-1000. PubMed ID: 26589761
    [TBL] [Abstract][Full Text] [Related]  

  • 57. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 58. Effects of controlled ovarian stimulation on thyroid stimulating hormone in infertile women.
    Du YJ; Xin X; Cui N; Jiang L; Yang AM; Hao GM; Gao BL
    Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():207-212. PubMed ID: 30731333
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is increased red cell distribution width an indicating marker of nonalcoholic steatohepatitis and fibrotic stage?
    Cengiz M; Candır BA; Yılmaz G; Akyol G; Ozenirler S
    World J Gastroenterol; 2013 Nov; 19(42):7412-8. PubMed ID: 24259972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.
    Younossi Z; Stepanova M; Ong JP; Jacobson IM; Bugianesi E; Duseja A; Eguchi Y; Wong VW; Negro F; Yilmaz Y; Romero-Gomez M; George J; Ahmed A; Wong R; Younossi I; Ziayee M; Afendy A;
    Clin Gastroenterol Hepatol; 2019 Mar; 17(4):748-755.e3. PubMed ID: 29908364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.